Biosenta Inc (TSE:ZRO)
:ZRO
Want to see TSE:ZRO full AI Analyst Report?
ZRO Stock Chart & Stats
C$0.08
-C$0.03(-11.36%)
At close: 4:00 PM EST
C$0.08
-C$0.03(-11.36%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.17
Previous CloseN/A
Volume1.00K
Average Volume (3M)2.93K
Market Cap
C$2.09M
Enterprise ValueC$2.94M
Total Cash (Recent Filing)C$7.81K
Total Debt (Recent Filing)C$865.55K
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding34,768,887
10 Day Avg. Volume5,790
30 Day Avg. Volume2,930
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-0.40
Price to Sales (P/S)3296.23
P/FCF Ratio-8.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash Flow TrendFree cash flow burn improved versus the prior annual period and FCF tracks net income near 1x, indicating operating losses are not driven by large non‑cash items. This reduces uncertainty in cash dynamics and improves visibility for financing needs over the medium term.
Debt Below Prior PeakAlthough debt has risen versus the most recent annual figure, total debt remains below the 2024 peak, suggesting some prior deleveraging or reduced peak leverage. That relative improvement can ease refinancing pressure and provides modest structural flexibility versus earlier peaks.
Smaller Net Losses Vs Prior PeakReported net losses are materially smaller than the unusually large loss in 2023, implying operational deterioration may have stabilized. Sustained smaller losses can lengthen runway, give management time to refocus strategy, and reduce immediate capital raising urgency.
Bears Say
Deeply Negative EquityA deeply negative equity position (TTM equity ~-10.6M against ~92K assets) signals accumulated deficits and potential insolvency risk. This structural weakness constrains financing options, limits strategic flexibility, and makes the company dependent on external recapitalization over the medium term.
Persistent Cash BurnConsistent negative operating and free cash flow (~-447K to -449K TTM) indicates ongoing cash burn and reliance on external funding or balance sheet actions. Over months this restricts investment, forces prioritization of liquidity, and increases execution risk absent durable revenue gains.
Very Small, Shrinking Revenue And Negative Gross ProfitA tiny, declining top line (TTM revenue ~940, down ~22% YoY) combined with negative gross profit undermines the business model's scalability. Structural revenue contraction and negative unit economics make sustainable margin recovery and profitable growth unlikely without major product or market changes.
Biosenta Inc News
ZRO FAQ
What was Biosenta Inc’s price range in the past 12 months?
Biosenta Inc lowest stock price was C$0.05 and its highest was C$0.17 in the past 12 months.
What is Biosenta Inc’s market cap?
Biosenta Inc’s market cap is C$2.09M.
When is Biosenta Inc’s upcoming earnings report date?
Biosenta Inc’s upcoming earnings report date is Sep 02, 2026 which is in 101 days.
How were Biosenta Inc’s earnings last quarter?
Currently, no data Available
Is Biosenta Inc overvalued?
According to Wall Street analysts Biosenta Inc’s price is currently Overvalued.
Does Biosenta Inc pay dividends?
Biosenta Inc does not currently pay dividends.
What is Biosenta Inc’s EPS estimate?
Biosenta Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosenta Inc have?
Biosenta Inc has 34,768,887 shares outstanding.
What happened to Biosenta Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biosenta Inc?
Currently, no hedge funds are holding shares in TSE:ZRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biosenta Inc
Biosenta Inc. develops, manufactures, and sells anti-microbial chemical compounds for household and industrial applications in Canada. It is involved in developing true, an anti-microbial, dual-action disinfectant that kills viruses, bacteria, mold, and germs on contact. The company also intends to manufacture and distribute Tri-Filler, an anti-microbial filler to perform filling and bulking functions. Biosenta Inc. was founded in 1986 and is based in Toronto, Canada.
Technical Analysis
BioNeutra Global
―
Lifeist Wellness
―
Psyched Wellness
―
Happy Supplements Inc.
―
Pure to Pure Beauty Inc.
―